NEAL KLEIMAN to Hemorrhage
This is a "connection" page, showing publications NEAL KLEIMAN has written about Hemorrhage.
Connection Strength
1.592
-
Bleeding Edge Technology: Retroperitoneal Hemorrhage and Its Implications for Transradial Access. Circ Cardiovasc Interv. 2018 02; 11(2):e006320.
Score: 0.450
-
The safety of clopidogrel. Expert Opin Drug Saf. 2011 Jan; 10(1):85-95.
Score: 0.273
-
Cautionary Tale or Exploratory Trek - Predicting Mortality Using the DAPT Score. Cardiovasc Revasc Med. 2020 12; 21(12):1515-1516.
Score: 0.135
-
Optimizing Management of Patients With Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: The Importance of Distinguishing Pre-Existing From New Onset Atrial Fibrillation. JACC Cardiovasc Interv. 2017 01 09; 10(1):101-103.
Score: 0.105
-
Are we there yet? deciding when it is safe (and wise) to stop clopidogrel after stent implantation. J Interv Cardiol. 2014 Apr; 27(2):127-30.
Score: 0.086
-
Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. JACC Cardiovasc Interv. 2013 Jul; 6(7):709-17.
Score: 0.082
-
Balancing hemostasis and thrombosis in interventional vascular medicine and surgery. Methodist Debakey Cardiovasc J. 2011 Oct-Dec; 7(4):19-23.
Score: 0.073
-
Impact of computerized dosing on eptifibatide-associated bleeding and mortality. Am Heart J. 2009 Dec; 158(6):1018-23.
Score: 0.064
-
Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. JACC Cardiovasc Interv. 2009 Nov; 2(11):1074-82.
Score: 0.063
-
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. Catheter Cardiovasc Interv. 2007 Jan; 69(1):73-83.
Score: 0.052
-
Combination therapy for acute myocardial infarction: will it survive? J Am Coll Cardiol. 2003 Apr 16; 41(8):1261-3.
Score: 0.040
-
Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. Circ Cardiovasc Interv. 2014 Jun; 7(3):365-73.
Score: 0.022
-
Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. Circ Cardiovasc Interv. 2011 Oct 01; 4(5):463-73.
Score: 0.018
-
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). Am J Cardiol. 2011 Jun 15; 107(12):1751-6.
Score: 0.018
-
The impact of postrandomization crossover of therapy in acute coronary syndromes care. Circ Cardiovasc Qual Outcomes. 2011 Mar; 4(2):211-9.
Score: 0.017
-
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009 Dec 10; 361(24):2318-29.
Score: 0.016
-
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009 Dec 10; 361(24):2330-41.
Score: 0.016
-
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009 May; 30(10):1195-202.
Score: 0.015
-
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation. 2007 Dec 04; 116(23):2669-77.
Score: 0.014
-
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006 Dec; 152(6):1042-50.
Score: 0.013
-
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004 Jul 07; 292(1):45-54.
Score: 0.011
-
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003 Feb 19; 289(7):853-63.
Score: 0.010